160 related articles for article (PubMed ID: 17453818)
1. Downregulation of missing in metastasis gene (MIM) is associated with the progression of bladder transitional carcinomas.
Wang Y; Liu J; Smith E; Zhou K; Liao J; Yang GY; Tan M; Zhan X
Cancer Invest; 2007 Mar; 25(2):79-86. PubMed ID: 17453818
[TBL] [Abstract][Full Text] [Related]
2. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2.
Chaffer CL; Brennan JP; Slavin JL; Blick T; Thompson EW; Williams ED
Cancer Res; 2006 Dec; 66(23):11271-8. PubMed ID: 17145872
[TBL] [Abstract][Full Text] [Related]
4. Differential regulation of cortactin and N-WASP-mediated actin polymerization by missing in metastasis (MIM) protein.
Lin J; Liu J; Wang Y; Zhu J; Zhou K; Smith N; Zhan X
Oncogene; 2005 Mar; 24(12):2059-66. PubMed ID: 15688017
[TBL] [Abstract][Full Text] [Related]
5. Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder.
Tong GX; Yee H; Chiriboga L; Hernandez O; Waisman J
Hum Pathol; 2005 Jul; 36(7):741-6. PubMed ID: 16084942
[TBL] [Abstract][Full Text] [Related]
6. E-cadherin promotes intraepithelial expansion of bladder carcinoma cells in an in vitro model of carcinoma in situ.
Bindels EM; Vermey M; van den Beemd R; Dinjens WN; Van Der Kwast TH
Cancer Res; 2000 Jan; 60(1):177-83. PubMed ID: 10646871
[TBL] [Abstract][Full Text] [Related]
7. Expression and regulation of MIM (Missing In Metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell lines.
Nixdorf S; Grimm MO; Loberg R; Marreiros A; Russell PJ; Pienta KJ; Jackson P
Cancer Lett; 2004 Nov; 215(2):209-20. PubMed ID: 15488640
[TBL] [Abstract][Full Text] [Related]
8. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder.
Karam JA; Shariat SF; Huang HY; Pong RC; Ashfaq R; Shapiro E; Lotan Y; Sagalowsky AI; Wu XR; Hsieh JT
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4400-6. PubMed ID: 17671122
[TBL] [Abstract][Full Text] [Related]
9. Cytokeratin expression during neoplastic progression of human transitional cell carcinomas as detected by a monoclonal and a polyclonal antibody.
Ramaekers F; Huysmans A; Moesker O; Schaart G; Herman C; Vooijs P
Lab Invest; 1985 Jan; 52(1):31-8. PubMed ID: 2578201
[TBL] [Abstract][Full Text] [Related]
10. Metastasis suppressor-1, MTSS1, acts as a putative tumour suppressor in human bladder cancer.
Du P; Ye L; Ruge F; Yang Y; Jiang WG
Anticancer Res; 2011 Oct; 31(10):3205-12. PubMed ID: 21965727
[TBL] [Abstract][Full Text] [Related]
11. Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer.
Dhawan D; Ramos-Vara JA; Stewart JC; Zheng R; Knapp DW
Urol Oncol; 2009; 27(3):284-92. PubMed ID: 18562222
[TBL] [Abstract][Full Text] [Related]
12. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder.
Karam JA; Lotan Y; Ashfaq R; Sagalowsky AI; Shariat SF
Urology; 2007 Sep; 70(3):482-6. PubMed ID: 17905101
[TBL] [Abstract][Full Text] [Related]
13. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
[TBL] [Abstract][Full Text] [Related]
14. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
[TBL] [Abstract][Full Text] [Related]
15. Differential expression analysis of MIM (MTSS1) splice variants and a functional role of MIM in prostate cancer cell biology.
Loberg RD; Neeley CK; Adam-Day LL; Fridman Y; St John LN; Nixdorf S; Jackson P; Kalikin LM; Pienta KJ
Int J Oncol; 2005 Jun; 26(6):1699-705. PubMed ID: 15870888
[TBL] [Abstract][Full Text] [Related]
16. Quantitative analysis of survivin mRNA expression in bladder transitional cell carcinomas.
Kitsukawa S; Aoyagi T; Noda K; Ito T; Yamamoto Y; Hosoda S; Otsuru N; Matsumoto T
Hinyokika Kiyo; 2008 Feb; 54(2):101-6. PubMed ID: 18323166
[TBL] [Abstract][Full Text] [Related]
17. Loss expression of uroplakin III is associated with clinicopathologic features of aggressive bladder cancer.
Matsumoto K; Satoh T; Irie A; Ishii J; Kuwao S; Iwamura M; Baba S
Urology; 2008 Aug; 72(2):444-9. PubMed ID: 18313120
[TBL] [Abstract][Full Text] [Related]
18. Tumour growth inhibition by an imidazoquinoline is associated with c-Myc down-regulation in urothelial cell carcinoma.
Liu H; Schwartz MJ; Hwang DH; Scherr DS
BJU Int; 2008 Apr; 101(7):894-901. PubMed ID: 18241249
[TBL] [Abstract][Full Text] [Related]
19. Interferon gamma regulates a unique set of proteins in fresh human bladder transitional cell carcinomas.
Aboagye-Mathiesen G; Ebbesen P; von der Maase H; Celis JE
Electrophoresis; 1999 Feb; 20(2):344-8. PubMed ID: 10197441
[TBL] [Abstract][Full Text] [Related]
20. MIM-B, a putative metastasis suppressor protein, binds to actin and to protein tyrosine phosphatase delta.
Woodings JA; Sharp SJ; Machesky LM
Biochem J; 2003 Apr; 371(Pt 2):463-71. PubMed ID: 12570871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
